1. Home
  2. COE vs IMUX Comparison

COE vs IMUX Comparison

Compare COE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COE

51Talk Online Education Group

HOLD

Current Price

$21.65

Market Cap

140.9M

Sector

Real Estate

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$12.29

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COE
IMUX
Founded
2011
2016
Country
Singapore
United States
Employees
N/A
66
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.9M
152.6M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
COE
IMUX
Price
$21.65
$12.29
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
3.5K
231.8K
Earning Date
06-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.32
$0.51
52 Week High
$56.13
$15.77

Technical Indicators

Market Signals
Indicator
COE
IMUX
Relative Strength Index (RSI) 39.63 54.33
Support Level $21.50 $0.74
Resistance Level $23.50 $13.30
Average True Range (ATR) 1.17 1.32
MACD -0.56 -0.52
Stochastic Oscillator 25.00 30.71

Price Performance

Historical Comparison
COE
IMUX

About COE 51Talk Online Education Group

51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: